4Teen4 closes $8M A round to test first-in-class cardiogenic shock drug Dec. 5, 2019 By Cormac Sheridan No Comments DUBLIN – 4Teen4 Pharmaceuticals GmbH raised €6.9 million (US$7.7 million) in a series A round to take procizumab, a first-in-class inhibitor of circulating dipeptidyl-peptidase 3 (cDPP3), into clinical trials for patients with cardiogenic shock. Read More